Abcam vs CRISPR Therapeutics
Abcam vs CRISPR Therapeutics, compared side by side on 16 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: Abcam is on 61/100 and CRISPR Therapeutics on 64/100.
Where each one leads
Abcam
Leads on none of the measures we hold for both companies.
CRISPR Therapeutics
- agent readiness: 44/100 against 22/100
- funding raised: $547M against $257M
At a glance
| Measure | Abcam | CRISPR Therapeutics |
|---|---|---|
| What it is | Global supplier of life science research tools, including antibodies, reagents, and assays. | Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology. |
| Category | Biotechnology, Life Sciences, Discovery Tools, Antibodies | Biotechnology, Gene Editing, Therapeutics, Pharmaceuticals |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | hardware | services | marketplace | platform | Platform |
| Founded | 1998 | 2013 |
| Headquarters | Cambridge, United Kingdom | Zug, Switzerland |
| Status | Active | Active |
Size, funding and growth
| Measure | Abcam | CRISPR Therapeutics |
|---|---|---|
| Total funding | $257M | $547M |
| Latest round | Series D | Series B |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | Abcam | CRISPR Therapeutics |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 61/100 | 64/100 |
| Traction | 40/100 | 40/100 |
| Team | 70/100 | 70/100 |
| Community | 15/100 | Not published |
| Search visibility | 16/100 | 13/100 |
| Quality | 78/100 | 88/100 |
| Agent readinessHow well an AI agent can read and act on the site | F (22/100) | D (44/100) |
| Domain ratingLink authority, 0-100 | 72/100 | 67/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | Abcam | CRISPR Therapeutics |
|---|---|---|
| Hosting | Not detected | Self Managed |
| Frameworks | Not detected | Jquery |
| Analytics | Not detected | Google Analytics 4 |
Abcam vs CRISPR Therapeutics: common questions
Which is better, Abcam or CRISPR Therapeutics?
On our 0-100 score CRISPR Therapeutics rates higher (64/100 against 61/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 16 data points above: read the rows that match what you are buying for.
How do Abcam and CRISPR Therapeutics compare on the numbers?
CRISPR Therapeutics leads on agent readiness (44/100 against 22/100), funding raised ($547M against $257M).
Read the full Abcam review and pricing or the CRISPR Therapeutics review and pricing. You can also browse other Abcam alternatives we track.